Literature DB >> 33641862

Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.

Rory M Shallis1, Amer M Zeidan1, Rong Wang2, Nikolai A Podoltsev3.   

Abstract

Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) comprise the BCR-ABL-negative classical myeloproliferative neoplasms (MPNs). These clonal myeloid diseases are principally driven by well-described molecular events; however, factors leading to their acquisition are not well understood. Beyond increasing age, male sex, and race/ethnicity differences, few consistent risk factors for the MPNs are known. PV and ET have an incidence of 0.5 to 4.0 and 1.1 to 2.0 cases per 100,000 person-years, respectively, and predict similar survival. PMF, which has an incidence of about 0.3 to 2.0 cases per 100,000 person-years, is associated with the shortest survival of the MPNs.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Epidemiology; Incidence; Myeloproliferative neoplasms; Prevalence; Survival

Mesh:

Year:  2021        PMID: 33641862     DOI: 10.1016/j.hoc.2020.11.005

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  3 in total

1.  The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry.

Authors:  Chris Varghese; Tracey Immanuel; Anna Ruskova; Edward Theakston; Maggie L Kalev-Zylinska
Journal:  Curr Oncol       Date:  2021-04-18       Impact factor: 3.677

2.  Familial essential thrombocythemia: 6 cases from a mono-institutional series.

Authors:  Vincenzo Accurso; Marco Santoro; Salvatrice Mancuso; Giorgia Vajana; Riccardo Tomasello; Cristina Rotolo; Giulia Camarda; Marta Mattana; Sergio Siragusa
Journal:  Clin Case Rep       Date:  2022-03-01

3.  Triple-Negativity Identifies a Subgroup of Patients with Better Overall Survival in Essential Thrombocythemia.

Authors:  Marco Santoro; Vincenzo Accurso; Salvatrice Mancuso; Mariasanta Napolitano; Marta Mattana; Giorgia Vajana; Federica Russello; Sergio Siragusa
Journal:  Hematol Rep       Date:  2022-08-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.